Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ocugen announces studies showing COVAXIN potentially effective against three key variants of .
OcugenMay 3, 2021 GMT
Potential effectiveness against multiple variants reduces the possibility of mutant virus escape
According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also suggested that COVA
Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2
COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant
Potential effectiveness against multiple variants reduces the possibility of mutant virus escape
According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at least 17 countries
MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that in a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that COVAXIN demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2, B.1.128.2. As previously disclosed, a study conducted by ICMR also suggested that COVAXI
Posted on 192
SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases. Sanofi, together with SIRION Biotech and Prof. Dirk Grimm, a world-renowned and pioneering scientist in the field of AAV biology and application working at Heidelberg University Hospital (Germany), will combine their proprietary technology platforms to create a next generation of AAV vectors. The goal of this collaboration is to develop new and modified AAV capsids that exhibit a safe prod
(2)
Joining forces to develop gene therapies for multiple life-threatening disorders SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of human diseases. Sanofi, together with SIRION Biotech and Prof. Dirk Grimm, a world-renowned and pioneering scientist in the field of AAV biology and application working at Heidelberg University Hospital (Germany), will combine their proprietary technology platforms to create a next generation of AAV vectors. The goal of this collaboration is to develop new and modified AAV capsids that exhibit
On the Move: LaVoieHealthScience Promotes DeScenza odwyerpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from odwyerpr.com Daily Mail and Mail on Sunday newspapers.